Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbenicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.77 |
| ▸ | RECQL | P46063 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | HPGD | P15428 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | TEK | Q02763 | 1/20 | 0.77 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | RARB | P10826 | 1/20 | 0.64 |
| ▸ | RARG | P13631 | 1/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbenicillin SCHEMBL11310979 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL3375 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL11310973 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL13662704 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL10520792 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL11604897 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL8402462 | 1.00 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL193749 | 0.99 | PTGS1 (0.76) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL28801787 | 0.99 | PTGS1 (0.76) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL7341688 | 0.99 | PTGS1 (0.76) | PTGS1KDM4ERECQLTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250249110-A1 | ANTIMICROBIAL PEPTIDE DERIVATIVE AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2025-08-07 | — | — | US | claimed |
| EP-3849562-B1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR | VENATORX PHARMACEUTICALS INC (US) | 2024-06-26 | — | — | EP | claimed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | claimed |
| EP-3781576-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-06-12 | — | — | EP | claimed |
| EP-3374391-B1 | ANTIBODY MOLECULE-DRUG CONJUGATES THAT SPECIFICALLY BINDS TO LIPOPOLYSACCHARIDE AND USES THEREOF | VISTERRA INC (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3529359-B1 | TUMOR INFILTRATING LYMPHOCYTES FOR USE IN THERAPY | UNIV MINNESOTA (US) | 2023-12-13 | — | — | EP | claimed |
| EP-4284941-A1 | DETECTING BETA-LACTAMASE ENZYME ACTIVITY | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2023-12-06 | — | — | EP | claimed |
| EP-2916820-B1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL TECH LLC (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3265119-B1 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | THERIVA BIOLOGICS INC (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| EP-0059645-B1 | METHOD AND KIT FOR IDENTIFICATION OF BETA-LACTAMASES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-06-04 | — | — | EP | claimed |
| EP-0085667-B1 | ENZYMATIC PROCESS FOR THE DETERMINATION OF ANTIBIOTICS CONTAINING A BETA-LACTAM NUCLEUS | U C B, S.A. (BE) | 1986-05-07 | — | — | EP | claimed |
| EP-0084925-B1 | 6-AMINOALKYLPENICILLANIC ACID 1,1-DIOXIDES AND DERIVATIVES AS BETA-LACTAMASE INHIBITORS | PFIZER INC. (US) | 1986-04-09 | — | — | EP | claimed |
| EP-0050805-B1 | BETA-LACTAMS, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-07-24 | — | — | EP | claimed |
| EP-0057606-B1 | SALTS OF PENICILLANIC ACID 1,1-DIOXIDE | PFIZER INC. (US) | 1985-05-02 | — | — | EP | claimed |
| EP-0085667-A2 | Enzymatic process for the determination of antibiotics containing a beta-lactam nucleus | U C B, S.A. (BE) | 1983-08-10 | — | — | EP | claimed |
| EP-0007690-B1 | PROCESS FOR THE PRODUCTION OF A POLYSACCHARIDE | TATE & LYLE PATENT HOLDINGS LIMITED (BM) | 1982-10-06 | — | — | EP | claimed |
| EP-0010846-B1 | METHOD AND APPARATUS FOR DETERMINING THE MINIMUM CONCENTRATION OF ANTIBIOTIC TO INHIBIT MICROORGANISM GROWTH | WARNER-LAMBERT COMPANY (US) | 1982-09-15 | — | — | EP | claimed |
| EP-0007717-B1 | CLAVULANIC ACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1982-08-11 | — | — | EP | claimed |
| EP-0003618-B1 | ANTIBACTERIAL COMPOSITION AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-01-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250249110-A1 | ANTIMICROBIAL PEPTIDE DERIVATIVE AND USE THEREOF | VIP, SLC47A1, SLC47A2 | PTGS1 2492/4885KDM4E 4347/4885RECQL 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.